AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer

WEDNESDAY, Aug. 12, 2026-- Anti-Müllerian hormone (AMH) appears to predict the benefit of chemotherapy plus endocrine therapy (CET) versus ET alone in premenopausal women younger than 55 years with hormone receptor-positive/human epidermal growth...